Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Small cell lung cancer (SCLC) is a very aggressive and proliferative disease, with little progress being having made for its treatment in decades. Our goal was to evaluate the effect of immune checkpoint inhibitors (ICIs) and identify optimal first-line interventions for the treatment of SCLC.

Methods

A systematic literature search of the Cochrane Library, PubMed and oncology conference proceedings were conducted. Randomized trials evaluating ICIs for SCLC were included. We use the risk of bias tool in RevMan 5.3 to assess the quality of studies. We used Stata version 15.0 to carry out data direct comparison and R version 4.0.2 to conduct the Bayesian network analysis.

Results

A total of 16 relevant clinical trials comprising 4,476 patients were included. W

SUBMITTER: Niu Z 

PROVIDER: S-EPMC8106042 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature